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Monoclonal Antibodies Recognizing the Non-Tandem
Repeat Regions of the Human Mucin MUC4 in Pancreatic
Cancer
Maneesh Jain1*, Ganesh Venkatraman1, Nicolas Moniaux1, Sukhwinder Kaur1, Sushil Kumar1, Subhankar
Chakraborty1, Grish C. Varshney3, Surinder K. Batra1,2*
1 Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska, United States of America, 2 Eppley Institute for Research
in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, Nebraska, United States of America, 3 Institute of Microbial Technology, Chandigarh, India

Abstract
The MUC4 mucin is a high molecular weight, membrane-bound, and highly glycosylated protein. It is a multi-domain
protein that is putatively cleaved into a large mucin-like subunit (MUC4a) and a C-terminal growth-factor like subunit
(MUC4b). MUC4 plays critical roles in physiological and pathological conditions and is aberrantly overexpressed in several
cancers, including those of the pancreas, cervix, breast and lung. It is also a potential biomarker for the diagnosis, prognosis
and progression of several malignancies. Further, MUC4 plays diverse functional roles in cancer initiation and progression as
evident from its involvement in oncogenic transformation, proliferation, inhibition of apoptosis, motility and invasion, and
resistance to chemotherapy in human cancer cells. We have previously generated a monoclonal antibody 8G7, which is
directed against the TR region of MUC4, and has been extensively used to study the expression of MUC4 in several
malignancies. Here, we describe the generation of anti-MUC4 antibodies directed against the non-TR regions of MUC4.
Recombinant glutathione-S-transferase (GST)-fused MUC4a fragments, both upstream (MUC4a-N-Ter) and downstream
(MUC4a-C-Ter) of the TR domain, were used as immunogens to immunize BALB/c mice. Following cell fusion, hybridomas
were screened using the aforementioned recombinant proteins ad lysates from human pancreatic cell lines. Three anti
MUC4a-N-Ter and one anti-MUC4a-C-Ter antibodies were characterized by several inmmunoassays including enzyme-linked
immunosorbent assay (ELISA), immunoblotting, immunofluorescene, flow cytometry and immunoprecipitation using MUC4
expressing human pancreatic cancer cell lines. The antibodies also reacted with the MUC4 in human pancreatic tumor
sections in immunohistochemical analysis. The new domain-specific anti-MUC4 antibodies will serve as important reagents
to study the structure-function relationship of MUC4 domains and for the development of MUC4-based diagnostics and
therapeutics.
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transmembrane subunit, ASGP-2, which contains two epidermal
growth factor-like domains in its extracellular part [3,4].
MUC4 is expressed in various epithelial tissues, including the
epithelia of fetal lungs and the adult respiratory tract from the
trachea to the collecting ducts lung trachea [5], colon [6],
endocervix [7], conjunctiva [8], cornea [9], salivary glands [10],
middle ear and eustachian tube [11]. In recent studies, a
progressive increase in MUC4 expression has been observed in
pancreatic intraepithelial neoplastic lesions, indicating its role in
disease development [12]. Previous studies from our laboratory
have shown that inhibition of MUC4 expression using anti-sense
or short-interfering RNA (siRNA) oligonucleotides specific to
MUC4 results in a decreased tumorigenicity and dissemination of
cancer cells [13]. Further, our recent studies have demonstrated
that MUC4 results in oncogenic transformation of mouse
fibroblasts [14], contributes to the drug-resistance of pancreatic
cancer cells by activating anti-apoptotic pathways [15], and is

Introduction
Human MUC4 is a highly glycosylated membrane-associated
mucin, consisting of a large 850-kD mucin-like subunit MUC4a,
and a membrane-bound 80 kD growth factor-like subunit
MUC4b [1,2]. MUC4a contains a central tandem repeat (TR)
domain containing variable numbers of 16 amino-acid residue
motifs that could be repeated up to 400 times per molecule. The
TR domain is flanked by a C-terminal cysteine rich domain and
an N-terminal domain which contains three repeats of 123 amino
acid residues [1]. MUC4b contains a cysteine rich domain, a
domain rich in N-glycosylation sites and three EGF-like domains
[1]. MUC4 is considered to be a human homologue of rat sialomucin complex (SMC, rat Muc4) because of similarities in
structural organization [1,3,4]. SMC is a heterodimeric glycoprotein composed of an O-glycosylated mucin subunit, ascites
sialoglycoprotein (ASGP-1), tightly bound to a N-glycosylated
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involved in the epithelial-to-mesenchymal transition in ovarian
cancer cells [16]. These studies from our laboratory and other
groups indicate the potential importance of this mucin in various
aspects of tumor biology.
We have previously generated a panel of monoclonal antibodies
directed against the TR region of MUC4 [17]. One of the antiMUC4 TR antibodies, 8G7, has served as a valuable reagent to
study the expression of the MUC4 mucin in various tissues and
unravel its involvement in various malignancies including,
pancreatic [12,18], gastric [19], cervical [20], ovarian cancers
[21], extra hepatic bile duct carcinoma [22], colangiocarcinoma
[23], and cutaneous squamous cell carcinoma. However, MUC4
contains many structural and functional domains both upstream
and downstream of the TR region [1,2], and many spliced forms
of MUC4 are completely devoid of TR region [24,25]. Further,
the TR region is heavily O-glycosylated. Given the alteration in
glycosylation status of solid tumors, it is possible that reactivity to
the antibody can be obscured in certain malignancies. Thus, the
structural complexity of MUC4, the existence of numerous splice
variants and glycoforms, and heavy O-glycosylation in the TR
domain warranted the generation of additional antibodies to fully
understand the structure-function relationship of various MUC4
domains under physiological and pathological conditions.
Here, we report the generation and characterization of a novel
anti-MUC4 MAbs that recognize the regions of MUC4a both
upstream and downstream of the TR domain. Purified recombinant MUC4 fragments, fused in frame with GST, were used as
immunogens and positive clones were selected based on their
reactivity in ELISA. Selected clones were characterized by their
reactivity toward MUC4 in immunoblotting, immunoprecipitation, immunofluorescence and flow cytometry using pancreatic
cancer cells. The non-TR anti-MUC4 MAbs developed in this
study may be promising reagents for the development of assays for
quantification of MUC4 in tissues and biological fluids, to study
the functional role of MUC4 in various diseases and potentially for
immunotherapy.

the MUC4 positive cell lines exhibited a characteristically distinct
band size which is consistent with our previous reports of VNTR
polymorphisms in MUC4 with HPAF/CD18, Colo357 and
QGP1 showing a single band and T3M4 expressing two bands
(allelic VNTR polymorphism). Unlike MAbs 2175, 2382 and 8G7,
MAb 2214 reacted predominantly with the low molecular weight
form of MUC4 but with the band pattern corresponding to the
VNTR polymorphism (Figure 2b). Mab 2214 also showed very
weak reactivity with the high molecular band corresponding to
those recognized by other antibodies in QGP1 and T3M4 lysates.
Immunoblot analysis of b-actin in the SDS-PAGE resolved lysates
indicated equal protein loading (Figure 2, inset). No reactivity
was observed with any antibody with the lysate of the MUC4
negative cell line MiaPaCa. None of the anti-MUC4a-C-Ter
antibodies reacted with MUC4 in the cell lysates in immunoblotting (data not shown).
The ability of antibodies to recognize MUC4 in the intact cells
was studied by immunofluorescence and flow cytometry. In the
methanol fixed and permeabilized assay HPAF/CD18 cells all the
selected MAbs exhibited specific staining for MUC4; no staining
was observed with the control anti-KLH antibody K2G6
(Figure 3). MAb 2214 showed a both membrane and perinuclear
staining, while MAbs 2175, 2382 and 2106 showed cytoplasmic
and membrane staining. The anti-TR MAb 8G7 showed strongest
reactivity due to the repetitive nature of the epitopes. Further,
none of the antibodies showed any reactivity with MUC4 negative
pancreatic cancer cell lines MiaPaCa or Panc1 (data not shown).
For cell surface staining, parformaldehyde-fixed (unpermmeabilized) cells were used and the binding of the antibodies was
analyzed by flow cytometry. MAb 2214 exhibited the strongest
reactivity with the cell surface in paraformaldehyde-fixed cells,
while the surface reactivity of MAbs 2175 and 2382 was weak and
the mean fluorescence intensity (MFI) values were comparable to
the values obtained with MAb 8G7 (Figure 4).
The domain-specific anti-MUC4 antibodies were also tested for
their ability to immunoprecipitate MUC4 using the HPAF/CD18
lysate. MAbs 2382 2175, and 2214 immunoprecipitated full-length
MUC4 from the total cell lysates, which was visualized when the
processed samples were resolved on SAS-agarose gel and
immunoblotted with anti-MUC4-TR MAb 8G7 (Figure 5).
The immunoprecipitated samples from various antibodies were
also immunoblotted with MAb 2214 due to its predominant
reactivity with a lower molecular weight form of MUC4. When
probed with MAb 8G7, the highest amount of MUC4 was
immunoprecipitated with 8G7, while MAb 2382 also resulted in
considerable enrichment of the 8G7 reactive protein bands. MAbs
2175 and 2214 also immunoprecipitated the full-length 8G7
reactive band but the enrichment was not as strong as observed
with MAbs 8G7 and 2382. Anti-C-terminal MAb 2106 and
negative control anti-KLH antibody K2G6 did not pull down any
8G7 reactive protein band. However, none of the tested antibodies
except 2214, immunopecipitated the MAb 2214-reactive low
molecular weight form of MUC4.
The ability of antibodies to detect MUC4 in tumor tissues was
tested by immunohistochemical analyses performed on pancreatic
cancer tissues. MAbs 2214, 2175 and 2382 showed positive
staining in the tumor tissue that was determined to be MUC4
positive based on its reactivity with anti-TR MAb 8G7 (Figure 6).
The pattern of staining with the new antibodies was similar to that
observed with 8G7 showing diffuse staining in both the membrane
and the cytoplasm of the tumor cells. No staining was observed
with Mab 2106 or the non-specific isotype matched control MAb
K2G6.

Results
The schematic structure of MUC4 and the recombinant
domains are indicated in Figure 1a. Following cell fusion, culture
supernatants from stable hybridomas were screened and the
positive hybridomas exhibiting high reactivity with the recombinant protein and negative reactivity with GST were cloned by
three rounds of limiting dilution. Seven stable clones reactive with
MUC4a-N-Ter and three clones reactive with MUC4a-C-Ter
were obtained (Table 1 and Figure 1b). MAbs 2172, 2173,
2175, 2212, 2213, 2214 and 2382 exhibited specific reactivity
toward MUC4a-N-Ter, while MAbs 2103, 2106 and 2107 were
specific to MUC4a-C-Ter. Further, none of the selected
antibodies showed any reactivity toward purified MUC4 TR
peptide, BSA or GST (data not shown). Similarly, previously
generated anti-MUC4 TR antibody 8G7 or anti-KLH antibody
K2G6 showed no reactivity toward the recombinant MUC4
domains.
The antibodies were further tested for their ability to specifically
recognize the MUC4 protein in the lysates of MUC4 expressing
pancreatic cancer cell lines by immunoblotting. Of the seven
MUC4a-N-Ter-specific antibodies only MAbs 2214, 2175 and
2382 recognized the MUC4 protein in the cell lysates (Figure 2).
MAbs 2215 and 2382 recognized high molecular weight protein
bands in the lysates of the MUC4 positive cells (HPAF/CD18,
Colo357, QGP1 and T3M4) (Fig. 2a and 2c) and the reactivity
pattern was similar to that of anti-TR MAb 8G7 (Fig. 2d). Each of
PLoS ONE | www.plosone.org
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Figure 1. Schematic structure of the recombinant MUC4 domains and reactivity of various anti-MUC4 antibodies. a) Schematic
structure of MUC4 and recombinant proteins used in the study. MUC4 is putatively cleaved at the GDPH site to generate an N-terminal mucin-type
subunit MUC4-a and a C-terminal growth factor-type subunit MUC4-b. Important domains of MUC4 are marked. Recombinant domains of MUC4- a
corresponding to the fragments upstream and downstream of the tandem-repeat (TR) domain were cloned and expressed as described in Materials
and Methods and termed MUC4-a-N-ter and MUC4-a-C-Ter, respectively. The nucleotide numbers corresponding to the boundaries of the
recombinant domains are marked and are described in Moniaux et al. and Choudhury et al (Ref 1 and 24, respectively) according to the original
numbering. Cys-cystein-rich domain EGF-epidermal growth factor-like domain; TM-transmembrane domain; CT-cytoplasmic tail. b) ELISA showing
the reactivity of anti-MUC4 MAbs to recombinant immunogens. The indicated MAbs were incubated with the 2.5 mg/ml of GST-tagged N-terminal
and tandem repeat recombinant domains of MUC4. The specificities were also tested against the MUC4 TR peptide, GST and a non-specific control
protein bovine serum albumin and the antibodies exhibited negative reactivity against these antigens. The assay also included a non-specific isotype
matched control K2G6.
doi:10.1371/journal.pone.0023344.g001
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Three of the antibodies raised against the region upstream of
the central TR domain 2214, 2175 and 2382, and one of the
antibodies generated against the downstream of the TR domain,
2106 showed strong reactivity against the respective recombinant
domains in ELISA. None of the antibodies recognize the nonspecific recombinant domains, GST or synthetic TR peptides.
These antibodies can potentially serve as useful reagents for the
development of MUC4 bioassays and can complement the existing
anti-MUC4 TR antibody or other antibodies reactive against the
carbohydrate epitopes present on mucins (DUPAN2, CA 19.9,
TAG 72). Growing evidence suggests that the MUC4 mucin, due
to its overexpression in several malignancies, is a potential marker
for diagnosis [27], particularly for the lethal pancreatic cancer
where its association with the early neoplastic lesions has been
established [29]. Another recent study has shown MUC4 to be a
novel prognostic factor of extra-hepatic bile duct carcinoma [22].
MUC4 expression was correlated with poor prognosis in smallsized lung adenocarcinoma [30]. All of these studies have shown
that MUC4 could be a key player in tumorigenesis; however, all of
these studies have analyzed MUC4 in tissue samples, which could
be limited by sampling errors, due to the heterogeneous expression
of tumor antigens. Hence, it would be logical to develop
quantitative assays for MUC4 in biological fluids, which will be
non-invasive, cost effective and easily automated. Due to the
variable size of the tandem repeat region, the antibody recognizing
the tandem repeat region could not be used for quantitative
purposes. The domain specific antibodies can potentially aid in
developing in vitro diagnostic assays to quantitate MUC4 in serum
and other biological fluids.
All the antibodies reactive with the region upstream of the
MUC4 TR domain were able to recognize MUC4 in the cell
lysates of MUC4-expressing pancreatic cancer cells. MAbs 2175
and 2382 recognized the full-length MUC4 with a high molecular
weight, with a band size similar to that recognized by anti-TR
MAb 8G7. The difference in signal strength of the non-TR and
TR antibodies could be attributed to the number of epitopes
available for the MAb to bind, since 8G7 recognizes the tandem
repeat region, which is represented multiple times in each
molecule, whereas the epitopes recognized by 2175 and 2382
are represented only once per molecule. In contrast, Mab 2214
exhibited strong recognition of a protein band of smaller size than

Table 1. Nomenclature, isotype and origin of Non-TR anti
MUC4 MAbs.

Clone ID

Immunogen

Isotype

2172 (5H8)

MUC4a-N-Ter

IgG2b, k

2173 (6G2)

MUC4a-N-Ter

IgG1, k

2175 (7F7)

MUC4a-N-Ter

IgG1, k

2212 (3A2)

MUC4a-N-Ter

IgG1, k

2213 (3F9)

MUC4a-N-Ter

IgG1, k

2214 (7E10)

MUC4a-N-Ter

IgG1, k

2382 (7H7)

MUC4a-N-Ter

IgG1, k

2103(5H7)

MUC4a-C-Ter

IgM, k

2106 (6E12)

MUC4a-C-Ter

IgG1, k

2107 (8A12)

MUC4a-C-Ter

IgG1, k

8G7

MUC4-TR peptide

IgG1, k

K2G6

KLH

IgG1, k

The generation of control MAbs 8G7 and K2G6 has been described in Moniaux
et al (Ref 17).
doi:10.1371/journal.pone.0023344.t001

Discussion
MUC4 is a large glycoprotein involved in physiology and
implicated in various disease states. Of particular importance is its
role in pancreatic cancer development and progression [2,26,27].
A number of recent studies have established the role of the
transmembrane mucin MUC4 in the pathogenesis of several
malignancies. MUC4 consists of two domains, namely MUC4a
which has the tandem repeat region and MUC4b which has the
trans-membrane region and also possesses growth factor like
domains [1,2]. Due to the polymorphism in the number of tandem
repeats [28] and the existence of various splice forms completely
devoid of the TR domain [25], the antibodies recognizing the nontandem repeat regions of the protein that could provide useful
information about its function, possible interacting partners and
more importantly can be used in quantitative assays.

Figure 2. Comparative immunoblot analysis for MUC4 expression in various pancreatic cancer cell lines using various antibodies. A
total of 20 mg of protein from cell extracts was resolved by electrophoresis on a 2% SDS-agarose gel, transferred to PVDF membrane, and incubated
with 2 mg/ml of MAbs 2175 (a), 2214(b), 2382 (c) or 1 mg/ml of anti-MUC4 TR Mab 8G7(d). The membrane was then probed with horseradish
peroxidase-labeled goat anti-mouse immunoglobulin. The signal was detected using an ECL reagent kit. The position of the detected bands is
indicated by arrows. For loading control, immunoblot for the detection of b-actin (inset a) was done on lysates of respective cells resolved on 10%
SDS-PAGE.
doi:10.1371/journal.pone.0023344.g002
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Figure 3. Immunofluorescence of MUC4 in CD18/HPAF cells with various anti-MUC4 MAbs. Cells were grown at low density on sterilized
cover-slides, fixed in ice-cold methanol at 220uC and were incubated with 10 mg/ml non-TR MAbs of 2214, 2175, 2382 and 2106, or 2 mg/ml of antiMUC4 TR MAb 8G7 (Control) and detected using FITC conjugated secondary antibody. Anti-KLH antibody K2G6 was used as an isotype control. Cells
were mounted on glass slides using anti-fade Vectashield mounting medium and observed under a ZEISS confocal laser scanning microscope
(magnification, 6630).
doi:10.1371/journal.pone.0023344.g003

those recognized by MAbs 8G7, 2175 and 2382. Despite their
lower molecular size, these bands mirrored the allelic variation
exhibited by the full-length MUC4 for the respective cell lines,
suggesting that Mab 2214 possibly reacts with an immature or
underglycosylated form of MUC4. Very faint bands corresponding
to the high molecular weight mature protein were still detected in
QGP1 and T3M4. The stronger signal strength of Mab 2214 with
the lower bands could be due to the abundance of an immature
MUC4 protein in the cancer cells. In cancer cells it is well

established that, due to aberrant and inefficient glycosylation,
mucins are hypoglycosylated and these immature forms continuously undergo repeated cycles of internalization, resulting in a
more immature form than the mature form. However, onmembrane deglycosylation (enzymatic or chemical) of resolved
protein bands did not enhance the reactivity of Mab 2214 with the
mature MUC4 bands (data not shown). However, in paraformadehyde fixed cells, MAb 2214 exhibited the highest reactivity with
the cell surface. The immature protein is unlikely to be present on
the cell surface, and possibly the fixation of cells with
paraformaldehyde exposed the MAb 2214 reactive epitope.
Further characterization of the low molecular weight form of
MUC4 reactive with MAb 2214 is underway.
Immunofluorescence analysis showed specific staining for

Figure 4. Cell-surface binding analysis of anti-MUC4 antibodies. Cells were harvested non-enzymatically, fixed with paraformaldehyde and incubated with the indicated antibodies. Following incubation with secondary antibody, cells were analyzed using BD
FACSCalibur. The mean fluorescence intensities (MFI) values obtained
with each antibody is indicated in parantheses.
doi:10.1371/journal.pone.0023344.g004

Figure 5. Immunoprecipitation of MUC4 using various MAbs to
MUC4. Protein lysates from the MUC4-expressing CD18/HPAF cells
were immunoprecipitated using 5 mg/ml of 8G7 (Tandem repeat MAb),
2382, 2214 and 2175 (Non-tandem repeat MAbs) and K2G6 (Isotype
matched control MAb) and were immunoblotted using MAbs 8G7 and
2214 as described in Materials and Methods.
doi:10.1371/journal.pone.0023344.g005
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Figure 6. Immunoperoxidase staining for MUC4 in pancreatic cancer tissues using non-TR MAbs. Paraffin sections were incubated with
the indicated test and control antibodies and binding was detected using VECTOR Universal staining Kit. MAb 8G7 was used at a concentration of
2 mg/ml, while all other antibodies were used at a concentration of 10 mg/ml.
doi:10.1371/journal.pone.0023344.g006

in vitro and in vivo conditions. Our recent studies have demonstrated
that MUC4 contributes to the chemoresistance in pancreatic
cancer cells by activating anti-apoptotic pathways and promoting
cell survival [15]. Hence it will be of interest to study the effect of
anti-MUC4 antibodies in inducing apoptosis in cancer cells and
augmenting their sensitivity to chemotherapeutic drugs. Further,
these antibodies also need to be evaluated for their utility in
radioimmunodiagnosis and radioimmunotherapy of MUC4 overexpressing tumors. Functional studies using the non-tandem repeat
MAbs may probably provide a better understanding of MUC4
mediated mechanisms in cancer progression. These antibodies
could also aid in understanding MUC4 structure-function
relationships, regulation of expression and possibly identify a
probable interacting partner on the tumor cell surface, which
could be the reason for the metastatic phenotype.
In conclusion, our studies indicate that MAbs 2175 and 2382
are highly specific in detecting the non-tandem repeat region of
the mucin MUC4 by various immunoassays. These domain
specific antibodies would serve as useful reagents to develop
quantitative assays, and are valuable tools to study MUC4
structure-function relationships and possibly target MUC4 for
therapy of solid tumors that overexpress MUC4.

MUC4 in membranes as well as in the cytoplasmic compartments
of HPAF/CD18 cells. The staining pattern was comparable with
the anti TR Mab 8G7 and their specificity to MUC4 was further
supported by the lack of signal in MUC4 negative cells. The
perinuclear staining of Mab 2214 further supports its reactivity to
the immature protein.
Due to its large size and multi-domain organization, MUC4 can
potentially interact with many proteins and these interactions
could be the key to various functions attributed to MUC4. Its
interaction with HER2 and the functional significance of this
interaction has been well studied [31,32]. However, there are
many other potential interacting partners of MUC4 that could
play an important role in modulating or mediating MUC4
function. MAbs 2175 and 2382 were able to immunoprecipitate
the MUC4 protein from the cell lysates of HPAF/CD18 cells and
could thus help in the isolation and identification of additional
MUC4 interacting partners. Further, the predominant reactivity
of MAb 2214 to lower molecular weight MUC4 is suggestive of a
different form of MUC4 which co-exists with the mature protein.
If, in fact, it is the immature form of the protein, then the MAb
2214 may potentially help in the isolation of various novel
interacting partners that may interact with this form of MUC4 and
unravel its functional significance.
MAbs 2214, 2175 and 2382 also recognized MUC4 expressed
in the cancer tissues by immunohistochemical analysis with the
reactivity pattern similar to that observed with anti-TR Mab 8G7.
None of the normal pancreatic ducts were stained, which is in
accordance with our earlier studies that have shown an absence of
MUC4 expression in the non-neoplastic ducts. The new antibodies
can be useful tools to corroborate the results obtained from 8G7,
suggesting the overexpression of MUC4 in various malignancies.
Further, due to the non-repetitive nature of their reactive epitope,
the newly developed antibodies will provide a more reasonable
measure of the extent of overexpression by negating the effects of
VNTR polymorphism. The anti-TR antibody 8G7, however,
would provide greater sensitivity of detection because of the
multiplicity of the epitopes. Thus, the combination of anti-TR and
anti-non TR MUC4 antibodies can provide better information
about the extent of MUC4 overexpression in the tumor tissues.
Efforts are underway to study the direct inhibitory effects of the
antibodies on cancer cell growth, motility and invasion under both
PLoS ONE | www.plosone.org

Materials and Methods
Ethics statement
The use of animals for immunization and isolation of spleen was
approved by the Institutional Animal Care and Use Committee
(IACUC) Protocol # 94-025-12 titled ‘‘Monoclonal Antibody
Core Facility Immunization Protocol’’.
Human pancreatic tumor tissues were obtained from the
University of Nebraska Medical Center (UNMC) Tissue Bank
and their use was approved via the UNMC Institutional Review
Board (IRB) approval # 491-97-EX.

Generation of recombinant MUC4 domains
Regions of MUC4-a on either side of the TR domain were
cloned and expressed, and purified proteins were used as
immunogens. Specific primers were designed using MUC4
sequence AJ000281 to amplify the fragments from nucleotides
587 to 3361 [MUC4a-Amino Terminal (MUC4a N-ter)] and
6
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ml/well of the peroxidase conjugated antibody (anti-mouse HRP,

from nucleotides 1 to 1293 [MUC4a-carboxy terminal (MUC4a
C-ter), representing the regions immediately upstream and
downstream of the TR domain, respectively (Figure 1a). BamHI
and an EcoRI restriction sites were added in the forward and
reverse primers, respectively, allowing in-frame cloning with the
GST and thrombin cleavage site of the pGEX-2TK vector
(Pharmacia). Amplification was done by the expand long RT-PCR
system (Roche) as described previously using JER103 and JER109
as templates for sequence AJ00281 and AJ010901, respectively
[1]. The constructs were sequenced to confirm the proper reading
frame and maintained in E. coli BL21 (New England Biolabs Inc.).
A 5 ml overnight preculture of each recombinant strain was used
to inoculate 1 liter of 26YTA medium (16 g tryptone, 10 g yeast
extract, and 5 g NaCl in 900 ml of deionized water, 100 mg/ml
ampicillin), and grown under agitation at 37C for 3 to 4 h to reach
an absorbance at 260 nm between 0.6–0.8, induced by 0.1 mM of
IPTG, and cultured for an addition of 3 to 4 h. Cultures were
centrifuged and washed three times in ice cold PBS, resuspended
in 5 ml of ice cold PBS, and sonicated. Protein lysates were
clarified by centrifugation and by filtration on a 0.22 mm filter.
Lysates were passed through a 5 ml Glutathione Sepharose Fast
Flow column (Pharmacia), washed three times with 5 column
volumes of PBS, and eluted with 10 ml of 15 mM reduced
gluthatione. Elution fractions of 1 ml were collected and 5 ml
aliquot of each fraction was resolved on 10% SDS-PAGE, and
proteins detected by coomassie blue staining. Fractions containing
pure GST-fusion proteins were pooled and quantified using the
BIO-RAD D/C protein estimation kit (BIO-RAD).

Amersham Biosciences, 1:2000 dilution in PBS) was added and
incubated for 1 h at 37uC. The plates were washed in PBST and
100 ml of TMB substrate (Dako Substrate) was added to each well
and incubated at 37uC. The reaction was arrested by adding
100 ml of 2 M sulfuric acid and the plates were scanned at 450 nm
in a Biotech ELISA plate reader.

Immunoprecipitation
Protein lysates from the MUC4-expressing HPAF/CD18 cells
were immunoprecipitated using 5 mg/ml of 2382, 2214, 2175,
8G7 (anti-TR antibody), and K2G6 (isotype matched control
MAb reacting with KLH). Antigen-Antibody complexes formed
were pulled down by using Protein A/G beads (Calbiochem) and
the complexes were solublized by using SDS-sample buffer
containing 2-mercaptoethanol. The samples were resolved on
2% SDS-agarose gel and were immunoblotted using 8G7.

Immunoblotting

The immunization and selection of MAbs were carried out
using established procedures at the UNMC Antibody Core Facility
[17]. Briefly, separate groups of mice (BALB/c) were immunized
by repeated IP injections of recombinant GST fusion proteins
MUC4a-N-Ter and MUC4a-C-Ter at two-week intervals. In
each group, immunization with recombinant protein was
alternated with the lysate of MUC4 positive HPAF/CD18 human
pancreatic cancer cells [17]. Sera from these mice were evaluated
in direct binding assays for antibody reactivity with the
recombinant MUC4 fusion protein, and GST was used as a
negative control. Once an appropriate antibody response was
observed in ELISA, the animals were given a final booster
injection with the recombinant protein four days prior to
exsanguination and splenectomy. Splenocytes were isolated and
fused with NS-1 and/or Sp2/0 myeloma cells. Hybridomas
producing the antibodies of interest were selected by screening for
specific antibody binding to the immunogen of interest (recombinant proteins and HPAF/CD18 lysate) and lack of binding to
irrelevant control antigens (GST and BSA).

A series of pancreatic cell lines were processed for protein
extraction and Western blotting using standard procedures [17].
Briefly, the cells were washed twice in PBS and scraped in
radioimmunoprecipitation assay (RIPA) buffer [50 mM Tris,
5 mM EDTA, 150 mM NaCl, 0.25% sodium deoxycholate; 1%
NP40 (pH 7.5)], containing protease inhibitor mixture (Roche
Diagnostics, Mannheim, Germany) and phosphatase inhibitors
(5 mM NaF and 5 mM Na3VO4; Sigma Chemicals, St. Louis,
MO), and kept at 4uC for at least 30 min. Cell lysates were passed
through the needle syringe or alternatively subjected to one freezethaw cycle to facilitate the disruption of the cell membranes. Cell
lysates were centrifuged at 14,000 rpm for 30 min at 4uC, and
supernatants were collected. Protein concentrations were determined using a BIO-RAD D/C protein estimation kit. Because of
the large size of MUC4, the proteins (20 mg) were resolved by
electrophoresis on a 2% SDS-agarose gel under reducing
conditions. SDS-PAGE was used for b-actin, (protein loading
control), and run under similar conditions. Resolved proteins were
transferred onto the polyvinylidene difluoride membrane and
subjected to the standard immunodetection procedure using
specific antibodies. For MUC4 immunodetection, anti-MUC4
mouse monoclonal antibody 8G7 (1 mg/ml) positive control, and
2 mg/ml of non-tandem repeat antibodies diluted in PBS were
used. Anti human b-actin (1:10000, Sigma AC-15) was used or the
protein loading control. Horseradish peroxidase-conjugated goat
anti-mouse (Amersham Biosciences) secondary antibody was used
at a dilution of 1:2000. The blots were processed with ECL
Chemiluminescence kit (Amersham Biosciences), and the signal
was detected by exposing the processed blots to X-ray films
(Biomax Films, Kodak, NY).

Screening for MUC4-positive Hybridomas

Confocal Immunofluorescence Microscopy

Immulon plates were coated with 50 ml of the antigenic
preparation (MUC4 recombinant proteins or GST or protein
lysates from MUC4 positive cell lines) at a concentration of
2.5 mg/well in bicarbonate buffer (pH 9.6). The plates were
incubated overnight at 4uC. The plates were washed in PBST and
the free binding sites of the wells were saturated to eliminate nonspecific binding of the immunoglobulins by incubating with
200 ml/well of 2% non-fat skimmed milk in PBS for 2 h at 37uC
and plates were washed in PBST. One hundred ml of the culture
supernatant was transferred from wells of culture plates into
corresponding wells in ELISA plates. Mouse pre-immune serum
was used as a negative control in each assay, incubated for 1 h at
37uC, and then the plates washed again in PBST. One hundred

For immunofluorescence staining, HPAF/CD18 cells were
grown at low density on sterilized glass cover slides overnight.
After washing with 0.1 M HEPES containing Hanks buffer, the
cells were fixed in ice-cold methanol at 220uC for 2 min.
Nonspecific blocking was done in 10% goat serum containing
0.05% Tween 20 for at least 30 min, followed by incubation with
the non-TR MAbs 2382, 2214, 2175 and anti-MUC4 TR MAb
8G7 was used as the positive control diluted in PBS. A non-specific
isotype matched antibody, K2G6, was used as a negative control
(1:100) for 1 h, at room temperature. Cells were washed 465 min
with PBS containing 0.05% Tween 20 (PBS-T) and then
incubated with FITC conjugated goat anti-mouse secondary
antibodies for 30 min. Cells were washed twice with PBS-T, and
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mounted on glass slides in anti-fade Vectashield mounting
medium (Vector Laboratories, Burlingame, CA). Immunostaining
was observed under a ZEISS confocal laser-scanning microscope,
and representative photographs were captured digitally using 510
LSM software.

For flow cytometry, cells were harvested non-enzymatically
using CellstripperTM (Mediatech, VA), washed with PBS (1% goat
serum) and counted. Cells were fixed for 30 min with 2%
paraformaldehyde (in PBS) and blocked with 5% goat serum. Cells
were then incubated with indicated antibodies (1 mg/106 cells) for
1 h on ice. Subsequently, cells were washed three times with PBS
and incubated with FITC conjugated anti-mouse antibody
(0.75 mg/ml, 1:300 dilution) for 1 h on ice. Cells were washed
again three times with PBS and analyzed using the BD
FACSCaliburTM flow cytometer.

and rehydrated in graded ethanol. Endogenous peroxidase activity
was quenched by incubating sections in 0.3% H2O2 in PBS for
20 min. Nonspecific binding was blocked by incubating the
sections with normal goat-serum for 30 min at room temperature.
Sections were then incubated with the anti MUC4 antibody
(1:100) diluted in PBS and a non-specific isotype matched
antibody, K2G6, as a negative control for 1 h, at room
temperature and washed with PBS-T (365 min) followed by
incubation with secondary antibody for 30 min. Slides were
washed (365 min) with PBS-T and incubated with the ABC
solution. The reaction color was developed by incubating sections
with 3,39-diaminobenzidine reagent. The slides were washed with
water and counterstained with hematoxylin. The sections were
then dehydrated in graded alcohols and mounted with Permount
permanent mounting media (Fisher Scientific, Fair Lawn, NJ). All
slides were observed under Nikon E400 Light Microscope and
representative photographs were taken.

Immunohistochemical Analysis
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